High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C

被引:190
作者
Griffin, JH
Kojima, K
Banka, CL
Curtiss, LK
Fernández, JA
机构
[1] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
关键词
D O I
10.1172/JCI5006
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels are associated, respectively, with either increased risk or apparent protective effects for atherothrombosis. The ability of purified LDL and HDL to downregulate thrombin formation, a contributor to atherothrombotic processes, was assessed. Purified HDL, but not LDL, significantly enhanced inactivation of coagulation factor Va by activated protein C (APC) and protein S, and HDL stimulated protein S-dependent proteolytic inactivation of Va by APC, apparently due to cleavage at Arg306 in Va. In normal plasma, added HDL enhanced APC/protein S anticoagulant activity in modified prothrombin-time clotting assays. When the anticoagulant potency of HDL was compared with phospholipid (PL) vesicles of well-defined composition using this assay, HDL appeared qualitatively different from PL vesicles because HDL showed only good anticoagulant activity, whereas PL vesicles were rather procoagulant. When 20 normal plasmas were tested using this clotting assay, apoA-I levels correlated with anticoagulant response to APC/protein S (r = 0.47, P = 0.035), but not with activated partial thromboplastin time-based APC resistance ratios. Because HDL enhances the anticoagulant protein C pathway in vitro, we speculate that HDL may help downregulate thrombin generation in vivo and that this anticoagulant action is one of HDL's beneficial activities.
引用
收藏
页码:219 / 227
页数:9
相关论文
共 60 条
[21]  
Folsom AR, 1998, CIRCULATION, V98, P207
[22]   HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum [J].
Fournier, N ;
Paul, JL ;
Atger, V ;
Cogny, A ;
Soni, T ;
delaLleraMoya, M ;
Rothblat, G ;
Moatti, N .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) :2685-2691
[23]   HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND CARDIOVASCULAR-DISEASE - 4 PROSPECTIVE AMERICAN-STUDIES [J].
GORDON, DJ ;
PROBSTFIELD, JL ;
GARRISON, RJ ;
NEATON, JD ;
CASTELLI, WP ;
KNOKE, JD ;
JACOBS, DR ;
BANGDIWALA, S ;
TYROLER, HA .
CIRCULATION, 1989, 79 (01) :8-15
[24]  
GRIFFIN JH, 1993, BLOOD, V82, P1989
[25]  
GRIFFIN JH, 1992, BLOOD, V79, P3203
[26]  
GRIFFIN JH, 1997, MED INTELL UNIT, P101
[27]   Delayed increase in high density lipoprotein phospholipids after ingestion of a fat load in normolipidemic patients with coronary artery disease [J].
Groener, JEM ;
Scheek, LM ;
van Ramshorst, E ;
Krauss, XH ;
van Tol, A .
ATHEROSCLEROSIS, 1998, 137 (02) :311-319
[28]  
HAMSTEN A, 1994, J INTERN MED, V236, P75
[29]   ACTIVATED PROTEIN-C RESISTANCE - MOLECULAR MECHANISMS BASED ON STUDIES USING PURIFIED GLN(506)-FACTOR-V [J].
HEEB, MJ ;
KOJIMA, Y ;
GREENGARD, JS ;
GRIFFIN, JH .
BLOOD, 1995, 85 (12) :3405-3411
[30]  
HEEB MJ, 1993, J BIOL CHEM, V268, P2872